Patient P-01367

Synthetic patientNBL-101 · Day 116 · 55–64 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

85%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 44 SC-12 recommended — Supportive Compound SC-12
Day 45 Patient declined — Not now
Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 50 GI-04 recommended — GI Support Protocol GI-04
Day 51 Patient accepted — Started GI-04 in the companion
Day 59 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days

Treatment adherence+3
Nutritional resilience-2
Toxicity+2

What helped?

Supportive Compound SC-12Day 44
Declined by patient
GI Support Protocol GI-04Day 50
Result: no meaningful change

LIFE OS recommendation

Dietary Support Protocol NP-02

59%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 27/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 69
- WearableHRV 25 ms, trending down
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 77 and rising
Autonomic recovery ↑45
- WearableResting HR 83 bpm
- Wearable2,753 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 53

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.5 · butyrate capacity 27/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 24 ms
Sleep: 6.7 h
Steps: 3,091
Resting HR: 82 bpm

Daily log: GI score 77, nutritional resilience 25, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01407	56%	S14	NP-02	no change	44
P-01866	54%	S14	—	—	40
P-01597	52%	S14	GI-04	no change	43
P-01440	50%	S12	GI-04	no change	51
P-01582	50%	S14	GI-04	no change	45
P-01615	48%	S14	ME-01	improved	48
P-01619	48%	S14	GI-04	worsened	38
P-01762	48%	S14	NP-02	no change	40
P-01772	48%	S20	NP-02	no change	50
P-01830	48%	S14	—	—	44
P-01736	47%	S03	ME-01	improved	46
P-01776	47%	S16	NP-02	no change	47